Cargando…
Gut microbiome composition and risk factors in a large cross-sectional IBS cohort
OBJECTIVE: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is difficult to diagnose and treat due to its inherent heterogeneity and unclear aetiology. Although there is evidence suggesting the importance of the microbiome in IBS, this association remains poorly defined. In...
Autores principales: | Agnello, Melissa, Carroll, Lauren N, Imam, Nabeel, Pino, Rodolfo, Palmer, Christina, Varas, Ignacio, Greene, Claire, Hitschfeld, Maureen, Gupta, Sarah, Almonacid, Daniel E, Hoaglin, Michael C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254124/ https://www.ncbi.nlm.nih.gov/pubmed/32518661 http://dx.doi.org/10.1136/bmjgast-2019-000345 |
Ejemplares similares
-
Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D)
por: Howell, Carol Angela, et al.
Publicado: (2022) -
A Swedish national adoption study of risk of irritable bowel syndrome (IBS)
por: Waehrens, Rasmus, et al.
Publicado: (2017) -
Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial
por: Yan, Ran, et al.
Publicado: (2020) -
Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute
por: Carbone, Florencia, et al.
Publicado: (2022) -
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)